Literature DB >> 163790

Antibody response to Epstein-Barr virus in infectious mononucleosis.

J Nikoskelainen, P Hänninen.   

Abstract

Altogether 171 serum specimens from 58 patients with heterophil antibody-positive infectious monomucleosis were studied for antibody response to Epstein-Barr virus (EBV). The sera were tested for fluorescent immunoglobulin G (IgG) and IgM gel-precipitating (GP) and complement-fixing (CF) antibodies to EBV. All 58 patients had IgG and IgM antibodies to EBV. Both IgG and IgM antibodies developed rapidly; the IgM antibodies disappeared within 8 to 10 weeks, whereas the IgG antibodies remained at an almost constant level. The development of IgG antibodies was so rapid that a fourfold or greater rise in titers was noted only in 22% of the patients. Both GP and CF antibodies to EBV (crude P3HR-1 Burkitt cell antigen) developed slowly; the mean titers kept rising for more than 12 weeks. The micro GP technique seemed to be more sensitive than the CF method, because 86% of the patients with infectious mononucleosis had GP antibodies compared with 72% having CF antibodies. In patients with infectious mononucleosis, a seroconversion or significant rise in GP antibodies was noted in 57%, whereas only 19% had a similar change in CF antibodies. The most promising of these antibody assays in the diagnosis of recent infections was the EBV-specific IgM antibody technique, which enables one to make the diagnosis on the basis of only one serum specimen. In cases where the acute-phase serum specimen is missing, the diagnosis can be made later by using the GP and CF techniques.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 163790      PMCID: PMC415022          DOI: 10.1128/iai.11.1.42-51.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  IgM antibodies to Epstein-Barr virus in infectious mononucleosis.

Authors:  H Schmitz; M Scherer
Journal:  Arch Gesamte Virusforsch       Date:  1972

Review 2.  Clinical significance of the EB herpesvirus infection in man.

Authors:  J H Joncas
Journal:  Prog Med Virol       Date:  1972

3.  Observations on childhood infections with the Epstein-Barr virus.

Authors:  G Henle; W Henle
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

4.  Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies.

Authors:  E Klemola; R Von Essen; G Henle; W Henle
Journal:  J Infect Dis       Date:  1970-06       Impact factor: 5.226

5.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

6.  Epstein-Barr virus antibody titres in mycosis fungoides.

Authors:  V K Hopsu-Havu; J Nikoskelainen
Journal:  Acta Derm Venereol       Date:  1972       Impact factor: 4.437

7.  Wart-virus antibodies and the prognosis of wart disease.

Authors:  S Pyrhönen; K Penttinen
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

8.  Raised antibody titres to E.B. virus in systemic lupus erythematosus.

Authors:  A S Evans; N F Rothfield; J C Niederman
Journal:  Lancet       Date:  1971-01-23       Impact factor: 79.321

9.  Complement-fixing and fluorescent antibodies in diagnosis of E.B.-virus infections.

Authors:  R N Sutton; E J Almond; S D Marston; R T Emond
Journal:  Lancet       Date:  1971-11-13       Impact factor: 79.321

10.  Mixed cryoimmunoglobulinaemia in infectious mononucleois and Cytomegalovirus mononucleosis.

Authors:  O Wager; J A Räsänen; A Hagman; E Klemola
Journal:  Int Arch Allergy Appl Immunol       Date:  1968
View more
  8 in total

1.  Epstein-Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis.

Authors:  J Nikoskelainen; E U Neel; D A Stevens
Journal:  J Clin Microbiol       Date:  1979-07       Impact factor: 5.948

2.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

3.  Role of rheumatoid factor in complement fixation and indirect hemagglutination tests for immunoglobulin M antibody to cytomegalovirus.

Authors:  N E Cremer; M Hoffman; E H Lennette
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

4.  Antibody formation by human tonsil cells in vitro.

Authors:  Z Baumöhl; B Kellerhals; W Stolp; I Lefkovits
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

5.  Rapid diagnosis of acute Epstein-Barr virus infection by an indirect enzyme-linked immunosorbent assay for specific immunoglobulin M (IgM) antibody without rheumatoid factor and specific IgG interference.

Authors:  D W Ho; P R Field; A L Cunningham
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

6.  Antibody reactivity to an Epstein-Barr virus BERF4-encoded epitope occurring also in Asp-57 region of HLA-DQ8 beta chain. Childhood Diabetes in Finland Study Group.

Authors:  P Parkkonen; H Hyöty; J Ilonen; H Reijonen; S Ylä-Herttuala; P Leinikki
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Primary Epstein-Barr virus infection in early childhood.

Authors:  S Krabbe; J Hesse; P Uldall
Journal:  Arch Dis Child       Date:  1981-01       Impact factor: 3.791

8.  Solid-phase radioimmunoassay of rubella virus immunoglobulin M antibodies: comparison with sucrose density gradient centrifugation test.

Authors:  O H Meurman; M K Viljanen; K Granfors
Journal:  J Clin Microbiol       Date:  1977-03       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.